This event has ended. Showing historical data.

GroupPOLYMARKET

Event GroupPOLYMARKETScience

FDA approves Sanofi’s Subcutaneous Sarclisa?

Name: FDA approves Sanofi’s Subcutaneous Sarclisa?
End: 2026-04-23T00:00:00.000Z

Total Volume

$7.90K

Events

Markets

Trade on Polymarket

FDA approves Sanofi’s Subcutaneous Sarclisa?

Vol

$7.90K

Events

Markets

Polymarket

Platform StatsQuick Platform Comparison

Polymarket

markets · $7.90K

Kalshi

markets · $0.00

Price Spread

0.0%avg

max 0.0%

Arbitrage

of 0 cross-platform

Volume DistributionTotal: $7.90K

100%

Polymarket leads

Price ChartMatched Markets Price Graph

1 market tracked

FDA approves Sanofi’s Subcutaneous Sarclisa?

No data available

Single-Platform Markets(1)

Market	Platform	Price
FDA approves Sanofi’s Subcutaneous Sarclisa?	Poly	2%

AI Analysis

Trader mode: Actionable analysis for identifying opportunities and edge

Top Probability

$7.90K

Volume

Markets

Platforms

About This Event

As of market creation, the FDA’s expected decision date for the specified application is April 23, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Sanofi’s Subcutaneous Sarclisa as a treatment for multiple myeloma by May 7, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License

AI-generated analysis based on market data. Not financial advice.

Custom AI Analysis Prompt

Tap to expand

Open in:ChatGPT Claude Gemini Grok DeepSeek

**Role:** Expert Prediction Market Analyst & Trader
**Objective:** Analyze the provided betting market data to deliver actionable insights, identify mispricings, and perform scenario analysis.
**Current Date:** Friday, July 10, 2026
**Context:** Prediction markets (Polymarket/Kalshi) are binary option markets where price (1-99) equals implied probability (1%-99%).

---

## 1. Event Snapshot
**Event:** FDA approves Sanofi’s Subcutaneous Sarclisa?
**Category:** Science | **Status:** active
**Resolution Date:** Apr 23, 2026 (Ended)
**Time Pressure:** Expired

**Description:** As of market creation, the FDA’s expected decision date for the specified application is April 23, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Sanofi’s Subcutaneous Sarclisa as a treatment for multiple myeloma by May 7, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License 

**Resolution Criteria (Sample):**
"As of market creation, the FDA’s expected decision date for the specified application is April 23, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Sanofi’s Subcutaneous Sarclisa as a treatment for multiple myeloma by May"

## 2. Market liquidity & Volume
* **Total Volume:** $7.9K
* **Total Liquidity:** $397
* **Activity Level:** High Turnover (Vol/Liq Ratio: 19.90)

## 3. Market Data (Prices & Odds)
### 1. FDA approves Sanofi’s Subcutaneous Sarclisa?
- **Polymarket** (End: Apr 23, 2026): Vol $7.9K
  DATA: [Yes: 2.5% (0.0%)] | [No: 97.5% (0.0%)]

---

## Analysis Instructions
Please provide a structured analysis using the following template:

### 1. Executive Summary
*   **Verdict:** [Most Likely Outcome]
*   **Confidence:** [0-100]%
*   **Timeframe:** [Immediate / Short-term / Long-term]
*   **Actionable Trade:** [Buy YES / Buy NO / Stay Away] (Include entry price target if applicable)
*   **Rationale:** 2-sentence summary of the core thesis.

### 2. Scenario Analysis
*   **Bull Case (Why YES goes up):** List specific catalysts or data points.
*   **Bear Case (Why YES goes down):** List specifics.
*   **Invalidation Point:** What happens to prove your thesis wrong?

### 3. Market Mechanics & Risks
*   **Liquidity/Volume Analysis:** Is the market efficient? Is it easy to exit?
*   **Cross-Platform Arbitrage:** (If applicable) Is the spread tradeable after fees?
*   **Time Decay:** How does time passing affect this position?

### 4. Signal Scores (0-100)
*   **Momentum:** [Score] (Price trend & velocity)
*   **Conviction:** [Score] (Volume backing the move)
*   **Information Edge:** [Score] (Likelihood of non-public info affecting price)
*   **Risk/Reward:** [Score] (Potential upside vs downside)

**Constraints:**
- Be direct and objective.
- Use bullet points for readability.
- If data is conflicting or insufficient, explicitly state "Low Confidence".

Tap text to select all

Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.

POLYMARKETScience